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The Biological influence and Clinical 
Relevance of Polymorphism within 
the nKG2D Ligands
Jianmin Zuo*, Fiyaz Mohammed and Paul Moss
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
NKG2D is a major regulator of the activity of cytotoxic cells and interacts with eight differ-
ent ligands (NKG2DL) from two families of MIC and ULBP proteins. The selective forces 
that drove evolution of NKG2DL are uncertain, but are likely to have been dominated by 
infectious disease and cancer. Of interest, NKG2DL are some of the most polymorphic 
genes outside the MHC locus and the study of these is uncovering a range of novel 
observations regarding the structure and function of NKG2DL. Polymorphism is present 
within all NKG2DL members and varies markedly within different populations. Allelic 
variation influences functional responses through three major mechanisms. First, it may 
drive differential levels of protein expression, modulate subcellular trafficking, or regulate 
release of soluble isoforms. In addition, it may alter the affinity of interaction with NKG2D 
or modulate cytotoxic activity from the target cell. In particular, ligands with high affinity 
for NKG2D are associated with down regulation of this protein on the effector cell, effec-
tively limiting cytotoxic activity in a negative-feedback circuit. Given these observations, 
it is not surprising that NKG2DL alleles are associated with relative risk for development 
of several clinical disorders and the critical role of the NKG2D:NKG2DL interaction is 
demonstrated in many murine models. Increased understanding of the biophysical and 
functional consequences of this polymorphism is likely to provide insights into novel 
immunotherapeutic approaches.
Keywords: polymorphism, single nucleotide, nKG2D ligands, binding affinity, cytotoxicity, immunologic, natural 
killer cells
inTRODUCTiOn
NKG2D is a dominant activating receptor on cytotoxic lymphocytes, including natural killer (NK) 
cells, γδ T cells, NKT cells, and αβ T cell subsets (1). Engagement of NKG2D with NKG2D ligands 
(NKG2DLs) on target cells triggers cytotoxicity or cytokine production and plays an important role 
in both innate and adaptive immune responses, including control of viral infection, tumorigenesis 
and pathogenesis of autoimmune diseases (2–4).
A striking feature of the NKG2D:NKG2DL interaction is that only a single gene encodes NKG2D 
while there are eight NKG2DL genes within the human genome. These NKG2D ligands comprise 
six cytomegalovirus glycoprotein UL16 binding proteins and two major histocompatibility complex 
class I polypeptide-related sequences (MICA/B). In mice, NKG2D ligands comprise five RAET1 
family members, three H60 proteins and MULT-1 (5–8). MICA and MICB contain α1, α2, and 
α3 domains together with a transmembrane domain and short cytoplasmic tail. In contrast, ULBP 
ectodomains comprise only the MHC-like α1 and α2 domain and ULBP1, ULBP2, ULBP3, and 
FiGURe 1 | Crystal structures of NKG2D-ligand complexes. (A) Ribbon representation of the MICA–NKG2D complex [PDB code 1HYR, Li et al. (10)]. NKG2D 
homodimer [NKG2D-A (brown) and NKG2D-B (green)] interacts with the α1 and α2 domains of monomeric MICA (orange). The clinically relevant polymorphic residue 
Met129 (red) in MICA is located distal to the MICA–NKG2D interface. Partially buried Met129 mediates non-polar interactions with MICA residues (ball and stick format) 
that protrude from the α2 helix. The α3 domain of MICA (residues Thr181-Ser274) has been omitted. (B) Ribbon representation of the ULBP6–NKG2D complex [PDB 
code 4S0U; Zuo et al. (13)]. NKG2D homodimer [NKG2D-A (brown) and NKG2D-B (green)] interacts with the α1 and α2 domains of ULBP6 (teal). The disease-
associated polymorphic residue Leu106 (red) in ULBP0602 is in close proximity to the ULBP6–NKG2D docking interface, inserting directly into the NKG2D hydrophobic 
pocket lined by several non-polar residues (ball and stick format). The figure was generated with PyMOL (Molecular Graphics System, Version 2.0 Schrödinger, LLC).
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ULBP6 are GPI-anchored receptors while ULBP4 and ULBP5 
encompass a membrane anchor and cytoplasmic tail (9).
Several crystal structures of the NKG2D/NKG2DL interac-
tion have been resolved, including NKG2D–MICA (10, 11), 
NKG2D–ULBP3 (12), and NKG2D–ULBP6 (13). These reveal 
that the symmetric NKG2D homodimer binds to a monomeric 
NKG2D ligand via a diagonal mode of engagement which is simi-
lar to TCR–pMHC interaction. In particular, the saddle-shaped 
NKG2D homodimer sits astride the NKG2D ligand helices with 
the NKG2D monomers A and B focused on the NKG2D ligand 
α2 and α1 helices, respectively (Figure 1) (13).
DAP10 is the binding partner for NKG2D and ligation and 
cross-linking of NKG2D leads to the recruitment of the p85 
subunit of PI3K and Grb2-Vav1-Sos1 complex to the phosphoryl-
ated DAP10. This elicits the phosphorylation of the kinases Jak2, 
Stat5, Akt, MEK1/2, and Erk. This in turn induces calcium flux, 
actin reorganization, degranulation and, finally, cytotoxicity to 
target cells. PI3K inhibitors can thus completely block cytotoxic 
activity (14).
All NKG2DL genes demonstrate considerable polymorphism 
(15–18) and this variation is present within each of the domains 
and with a relatively random distribution, a feature in contrast to 
the focused variation that is observed with MHC class I genes (19, 
20). Polymorphism is most significant within the MICA and MICB 
genes (17) where 62 single nucleotide polymorphisms (SNP) and 
25 SNPs have been identified, respectively. In relation to the ULBP 
gene family, 28, 12, 10, 20, 10, and 14 SNPs have been reported 
within ULBP1-6 (15, 17, 21, 22). Interestingly, polymorphisms 
within MICA and MICB are distributed throughout the three 
extracellular α1–α3 domains and there are no identified coding 
polymorphisms within residues 40–89 within the section of the 
α1 domain that is predicted to mediate binding with NKG2D 
(9, 23). This profile is somewhat different to the profile of ULBP 
polymorphism where several variants are predicted to influence 
directly the site of NKG2D binding.
The frequency of individual MICA and MICB alleles varies in 
different populations around the world. In particular, MICA*008 
is the most frequent allele worldwide (9) (except in South 
American Indians) (24) followed by MICA*002, MICA*010, 
MICA*009, and MICA*004. The MICB gene is more homoge-
neous, with MICB*005 being the most common allele and less 
representation from MICB*002, MICB*004, MICB*008, and 
MICB*014 (9). Population-based variations in polymorphism are 
also a dominant feature and with wide variation in the frequency 
of SNPs within ULBP in Euro-Caucasoid, Afro-Caribbean, and 
Indo-Asian individuals (15) and most variation focused within 
ULBP3, ULBP4, and ULBP6 (15, 16).
POLYMORPHiSM wiTHin nKG2D 
LiGAnDS ReFLeCTS THe iMPACT OF 
DiFFeRenTiAL SeLeCTive FORCeS 
wiTHin evOLUTiOn
An important question within NKG2DL biology relates to the 
evolutionary pressures that have driven gene duplication and 
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polymorphism within MIC and ULBP family members. The 
expression of each gene is differentially regulated within tissues 
and it is likely that temporal and tissue-specific regulation of 
NKG2DL has served to optimize control of infectious challenges 
while limiting the development of autoimmune complica-
tions (16). Evidence for this effect may be seen in relation to 
the ULBP0601 and ULBP0602 proteins, where ULBP0601 
homozygosity is associated with increased cytotoxic activity in 
comparison to the ULBP0602 variant (13). Viral infections may 
have represented a particularly important selective force as viral 
immunoevasins generally bind only to specific ligands and no 
single viral immunoevasin has yet been described which can bind 
to all NKG2DL family members.
Assessment of NKG2DL polymorphism within different spe-
cies might also provide some clues as to the pace and potential 
determinants of gene diversification. Meyer et al. (25) sequenced a 
range of MIC genes from non-human primates and demonstrated 
that these most likely derive from a single common MICB-like 
ancestor (26). Much of the polymorphism within ULBP genes 
appears to have arisen very early in the development of Homo 
sapiens and prior to migration out of Africa (15, 27). However, 
the pattern of diversity varies markedly across the globe and is 
likely to reflect differential selection to pathogens within different 
environments (9, 24). Some inferences may be drawn from the 
evolution of the KIR genes where, in addition to infection, a role 
in mediating successful pregnancy outcome also appears to be 
important (28).
THe CLiniCAL iMPORTAnCe OF 
POLYMORPHiSM wiTHin nKG2D 
LiGAnDS
Polymorphisms within NKG2DL alleles have been identified as 
risk factors for a range of different clinical disorders. As discussed 
above, NKG2DL expression is increased by inflammatory stimuli 
(29) and as such the strong association of ULBP6 SNP (rs9479482) 
with Alopecia Areata is compatible with its autoimmune patho-
genesis (AA) (30, 31). Indeed, NKG2D+ T cells have been identi-
fied as important mediators in the initiation of this disease (32). 
The first association of MICA polymorphism with autoimmune 
disease was observed by Mizuki et al. (33) in Behçet’s disease and 
this has been followed by 12 further reports (Table 1).
Viral infection is a potent stimulus for NKG2DL expression 
and an early report identified that MICA polymorphism was 
associated with increased risk of CMV reactivation in HIV-
seropositive patients (43). Strikingly, genome-wide association 
study analysis of 2,008 patients with pediatric Dengue shock 
syndrome and 2,018 controls from Vietnam demonstrated that 
the MICB polymorphism rs3134899 was one of only two associ-
ated risk alleles with a per-allele odds ratio of 1.34 (44). Moreover, 
a replication study in Thai patients confirmed these findings (46), 
which were also apparent in patients with less severe clinical 
phenotypes of dengue as well as an infant group (45, 46). As such, 
the association of MICB alleles with dengue is one of the most 
well characterized allelic associations of a non-HLA gene with 
any infectious disease.
Cancer may be been an important selective force in NKG2DL 
evolution and expression is increased markedly during cell trans-
formation. Several reports have demonstrated an association 
between NKG2DL alleles and a range of different cancer subtype 
and it will be of interest to see if this is replicated in future studies 
(34–42). Tumor-specific immune responses are also central in 
disease control and are exemplified in stem cell transplantation 
(HSCT) (60) where the curative effect relies mainly on the graft 
versus leukemia effect. NKs contribute to alloreactive responses 
(61, 62) and NKG2DL polymorphism appears to play a particu-
larly important role in this setting (63). Again, the MICA-129 
Met/Val dimorphism is informative with higher relapse rates 
observed in association with the MICA-129Met/Met homozy-
gous genotype (57) and increased incidence of cGVHD with 
MICA-129 Val/Val homozygotes (59). This has been interpreted 
as reflecting stronger NK and CD8+ T cell activation in the pres-
ence of the MICA-129Met allele although the longer term effects 
may be mitigated by subsequent down regulation of NKG2D on 
effector cells. We also investigated the impact of ULBP in 371 
SCT patient–donor pairs and related this to clinical outcome (58), 
observing a strong association between the ULBP0602 allele and 
overall survival. This effect might reflect either the direct conse-
quence of cytotoxic activity of NK and T cells against tumor cells 
or a regulatory role of the NK subset on subsequent development 
of the alloreactive T cell response (64–67).
THe FUnCTiOnAL iMPACT OF 
POLYMORPHiSM wiTHin nKG2D LiGAnD 
PROTeinS
A major ambition is now to understand the biological importance 
of physiological variation within the NKG2DL proteins and how 
this information may be used both to understand established 
disease associations and to potentially develop novel immuno-
therapeutic approaches.
In this review, we address this challenge in relation to the 
influence of polymorphism (Figure 2) on (1) expression level of 
NKG2DL proteins, (2) differential affinity for NKG2D, and (3) 
modulation of cytotoxic activity.
The influence of Polymorphism on the 
expression of Surface and Soluble Forms 
of nKG2DL
Perhaps the most immediate influence of NKG2DL polymor-
phism is that it may modulate the magnitude of protein expression 
at the cell surface. Indeed, use of a functional genomics system 
whereby a single copy of MICA cDNA can be stably integrated 
into CHO cells revealed differential transcriptional activity that 
varied by sixfold across four different alleles and correlated with 
protein expression (68). Two MICA polymorphisms associated 
with increased risk of HCV-related hepatocellular cancer are both 
located at the 5′ flanking region of MICA, rs2596542 (39) being 
4.7 kb and rs2596538 (40) 2.8 kb upstream of the MICA gene. 
Of interest, the rs2596538 allele is located at a binding site for 
transcription factor specificity protein 1 and both SNPs modulate 
the level of soluble MICA protein due to relative transcriptional 
TABLe 1 | The clinical relevance of polymorphism within NKG2D ligands.
nKG2DL Single nucleotide 
polymorphisms
Diseases Reference
Malignancy 
association
MICA 129-Met/Val Nasopharyngeal carcinoma Douik et al. (34)
MICA MICA-5.1 Oral squamous cell carcinoma Tamaki et al. (35, 36)
MICA MICA-5.1 Breast cancer Lavado-Valenzuela et al. (37)
MICA 213 thr and 251 gln Cervical cancer Jumnainsong et al. (38)
MICA rs2596542, rs2596538 Hepatitis C virus (HCV)-induced hepatocellular 
carcinoma (HCC)
Kumar et al. (39); Lo et al. (40); Goto et al. (41)
MCIA rs2596542G/A 129Met/Val; 
251Gln/Arg 175Gly/Ser; triplet 
repeat
Hepatitis B virus-induced hepatocellular carcinoma Tong et al. (42)
Virus infection MICA MICA-5.1 CMV reactivation in HIV-infected patients Moenkemeyer et al. (43)
MICB rs3132468 Dengue shock syndrome and non-severe dengue Khor et al. (44); Whitehorn et al. (45); Dang 
et al. (46)
Autoimmune 
diseases
MICA 129-Met/Val Chronic Chagas heart disease Ayo et al. (47)
MICA 129-Met/Val Ankylosing spondylitis Amroun et al. (48)
MICA rs1051794 Rheumatoid arthritis Kirsten et al. (49)
MICA 129-Met/Val Inflammatory bowel disease Lopez-Hernandez et al. (50); Zhao et al. (51)
MICA 129-Met/Val Lupus erythematosus Yoshida et al. (52)
MICA 129-Met/Val Type I diabetes Raache et al. (53)
MICA 129-Met/Val Psoriatic disease Pollock et al. (54)
MICA Triplet repeat microsatellite Behçet disease Mizuki et al. (33)
MICA MICA-A9 triplet repeat Psoriatic arthritis Gonzalez et al. (55)
ULBP6 Rs1543547 Diabetic nephropathy Mcknight et al. (56)
ULBP6 Rs9479482 Autoimmune alopecia Petukhova et al. (30)
HSCT MICA 129-Met/Val Chronic GvHD Boukouaci et al. (57)
ULBP6 ULBP0601/ULBP0602 HSCT overall outcome Antoun et al. (58)
MICA 129-Met/Val HSCT clinical outcome Isernhagen et al. (59)
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activity at the MICA locus (39, 40). The rs1051792 SNP of the 
MICA gene resulting in the MICA-129Met/Val dimorphism 
was the first MICA polymorphism for which a functional 
consequence was described and the MICA-129Met variant is 
associated with particularly strong NKG2D engagement. The 
effect of this exchange is more subtle, in that the MICA-129Met 
variant is associated with increased transcriptional activity but 
protein retention within intracellular compartments (69) and 
higher serum MICA levels are seen in patients with hepatitis B 
who are homozygous for the MICA-129Val allele (42). As such, 
polymorphism can influence not only the magnitude of protein 
expression but also the pattern of expression within the cell. Our 
own studies have focused on polymorphism within ULBP6 (13) 
where stably integrated CHO cell lines with a single copy of the 
ULBP0601 and ULBP0602 alleles, and primary patient samples, 
did not reveal any difference in surface expression or shedding 
according to genotype.
As such, polymorphisms within NKG2DLs that act to modu-
late protein expression, subcellular location, and surface shedding 
are important regulators of differential NKG2DL activity.
The importance of nKG2DL Polymorphism 
on Binding Affinity to nKG2D
Engagement of NKG2D ligands with NKG2D is a crucial step 
in the activity of many cytotoxic cells. Again, study of the MIC-
A129 Met/Val dimorphism has been crucial in studies of how this 
may be influenced by allelic variation. Steinle et al. transfected 
a range of nine different MICA alleles into a reporter cell line 
and, after determining equivalent levels of cell surface expression, 
then interrogated their binding to soluble NKG2D. A hierarchy of 
fluorescent intensity was observed, with 5 alleles demonstrating 
stronger binding compared to the other 4 (70). Interestingly, the 
presence of methionine at position 129 (Met129) was the sole 
determinant of strong binding. In subsequent work, Isernhagen 
and colleagues expressed two MICA*0701 variants, with either 
methionine (the wild-type amino acid) or valine at position 129, 
and examined NKG2D affinity on a range of different cell types. 
The slope of NKG2D engagement in relation to increasing MICA 
expression intensity was steeper for the MICA-129Met variant, 
indicating higher avidity compared to the MICA-129Val variant 
(59). Based on the crystal structure of MICA*01 (10), this bial-
lelic position does not participate directly in the MICA–NKG2D 
interface but may indirectly modulate NKG2D binding via a 
conformational change (Figure 1A). The methionine side chain 
protrudes from the β-sheet base and mediates an extensive net-
work of non-polar interactions with Gln136, Ala139, and Met140 
from the N-terminal helical stretch of α2, a region that is in close 
proximity to the MICA–NKG2D interface (11). It is conceivable 
that this conformation within the MICA-Met129 variant permits 
optimal contacts with bound NKG2D which is presumably lost 
in the MICA-Val129 form and this may account for the differing 
ligand binding affinities associated with the MICA-129Met/Val 
dimorphism.
We have also examined the binding of NKG2D to recom-
binant forms of the two major ULBP6 alleles (ULBP0601 and 
ULBP0602), using surface plasmon resonance (13). Strikingly, 
ULBP0602 demonstrated a very high affinity for its ligand with 
fast binding and slow dissociation. Indeed, the measured affinity 
of 15.5  nM is over 10-fold higher than the equivalent binding 
FiGURe 2 | The polymorphism of NKG2D ligands will affect the biological function of NKG2D ligands in multiple levels, including (A) different transcription, 
(B) different expression level on cell surface, (C) different binding affinity, (D) different soluble ligands shedding. Collectively, these will ultimately affect the 
(e) downstream signaling and cytotoxicity function.
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for ULBP0601 and substantially greater than any other ULBP 
family member. The structure of the NKG2D/ULBP0602 inter-
action revealed hydrophobic contacts at the ULBP0602/NKG2D 
interface sufficient to explain this difference as position Leu106 
in ULBP0602, located at the NKG2D receptor ligand interface, 
inserts directly into the center of the hydrophobic patch B of 
NKG2D, forming numerous non-polar contacts with surround-
ing residues (Tyr152, Ile182, Met184, and Tyr199) (Figure 1B). In 
contrast, ULBP0601 has a charged and lengthy Arg at this posi-
tion and its introduction within this predominantly hydrophobic 
environment is likely to be detrimental for NKG2D binding.
Collectively, these studies reveal that variation in the affinity of 
the interaction with NKG2D is likely to have acted as an impor-
tant selective force in the polymorphism within NKG2D ligands.
Polymorphism within nKG2DL Have an 
important influence on Cytotoxic Activity 
of effector Cells
The most important functional outcome of NKG2DL:NKG2D 
engagement is the degree of cytotoxic activity from the effector cell. 
A range of studies (13, 59, 68) have indicated subtle differences in 
NKG2DL structure can translate into significant variation in the 
cytotoxic capacity of effector cells. This has demonstrated clearly 
within the MIC-A family by increased levels of NK cell cytotox-
icity and cytokine production following engagement with cells 
expressing the high-affinity MICA-129Met allele in comparison 
to those with surface expression of MICA-129Val (59). A compa-
rable profile was observed in relation to co-stimulation of CD8+ 
T cells where, again, the 129Met allele provided stronger signaling 
to NKG2D+ CD8+ cells in concert with TCR engagement.
In light of these findings it might be considered that the evo-
lution of high-affinity NKG2DL alleles would result inexorably 
into positive selection within a population. However, as almost 
always in biology, there is clearly a balance in the relation to the 
optimal affinity for NKG2DL:NKG2D binding. In particular, as 
the level of NKG2DL protein expression increases on the surface 
of a target cell, as might occur in the setting of viral infection 
or transformation, this can lead to dramatic down regulation of 
NKG2D expression on the effector cell in  situations where the 
NKG2DL ligand has a high affinity for NKG2D. As such, alleles 
such as MICA-129Met might offer a cytotoxic advantage against 
targets with low levels of NKG2D expression but become coun-
terproductive as they drive the “NKG2D exhaustion” of effector 
cells following high levels of expression due to cellular stress.
Striking differences are also observed in the cytotoxic capacity 
of NK cells taken from different donors (68). A comparison of 
effector cell activity from 22 healthy donors revealed marked 
interindividual variation in the cytotoxic ability and, surpris-
ingly, this was correlated both positively and negatively to MICA 
expression level in different donors. The authors argue that 
individual responses are “tuned” to different “dose bandwidths” 
of NKG2DL expression, again challenged the simple hypothesis 
that higher receptor levels promote greater responsiveness.
We also observed that effector cells expressing the high-
affinity ULBP6 allele, ULBP0602, elicited weaker killing from a 
range of effector NK and T cells compared to ULBP0601, and was 
correlated with less downregulation of NKG2D (13). We suggest 
6Zuo et al. Polymorphism of NKG2D Ligands
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that this may result either from the ultra stable binding nature 
of the NKG2D/ULBP0602 interaction, which equates to a t1/2 of 
~550 s at 25°C, acting to limit serial triggering of NKG2D recep-
tors (71, 72). Alternatively, shedding of the high-affinity soluble 
ULBP0602 can inhibit NKG2D binding to the NKG2D ligands 
on the cell surface.
exploiting the Translational Potential of 
Polymorphism within nKG2DL
The reports of polymorphism within NKG2D ligands, particu-
larly MICA and ULBP6, and disease risk indicate that NKG2DL 
family members may represent an important therapeutic targets 
for treatment. The interaction of NKG2D and NKG2D ligands 
has been shown to be particularly important in the control of 
malignant disease. In vivo studies in murine models have shown 
that expression of NKG2D ligands on tumor cells is an important 
determinant of tumor control (73) and as such it is no surprise 
that tumor progression is associated with selection for tumor 
variants which are able to evade NKG2D-mediated immune 
recognition. In the setting of inflammatory disease, one potential 
strategy might be to downregulate NKG2D receptor expression 
on T  cells and NK  cells through soluble NKG2D ligands or 
immune suppressive cytokine (74, 75). In the setting of malignant 
disease, considerably more information is required on the profile 
of NKG2DL expression within individual tumor and how this is 
related both to the profile of somatic mutations within the tumor 
and the tumor microenvironment. Cytokines such as TGF-β have 
also been shown to regulate NKG2DL expression and represent 
a further influence on ligand regulation within the tumor micro-
environment (76).
As such, interventions that can modulate the functional 
outcome of the NKG2D:NKG2D interaction may represent 
important and novel immunotherapeutic approaches (77). This 
indicates the requirement for continuing research to understand 
and exploit the lessons that can be derived from the extensive 
polymorphic variation within this remarkable ligand interaction.
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